Premium
Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair
Author(s) -
Henry Jeffrey J. D.,
Delrosario Lawrence,
Fang Jun,
Wong Sze Yue,
Fang Qizhi,
Sievers Richard,
Kotha Surya,
Wang Aijun,
Farmer Diana,
Janaswamy Praneeth,
Lee Randall J.,
Li Song
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201900544
Subject(s) - myocardial infarction , contractility , cardiac function curve , medicine , heart failure , cardiology , ejection fraction , fibrosis , regeneration (biology) , tissue engineering , infarction , ventricular remodeling , biomedical engineering , microbiology and biotechnology , biology
Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound‐guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.